Skip to content

Study · Animal study (in vivo) · mouse · 1995

2 results

Gonadotropin-releasing hormone agonist suppression of ovarian tumorigenesis in mice of the Wx/Wv genotype.

Blaakaer J, Baeksted M, Micic S, Albrectsen P, Rygaard J, Bock J

Biology of reproduction1 Oct 1995Cited by 28 (Europe PMC)

PMID8547469 (opens in a new tab)DOI10.1095/biolreprod53.4.775 (opens in a new tab)PepBankPUB-08547469
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In Wx/Wv mice, no tumors occurred in 11 goserelin-treated mice versus bilateral ovarian adenomas in all 15 sham-treated mice (p < 0.00005).

    In plain wordsIn mice, no tumors occurred with goserelin, while all sham-treated mice developed ovarian adenomas.

    Peptide
    Goserelin
    Outcome
    DecreaseOvarian tubular adenomas
    Study

    mousen = 26

    Wx/Wv mice
    Comparator
    Sham injection
    Outcome group
    Tumor growth · Cancer
    Studied dose
    3.6 mg depot every 28 days · injection · from age 7 days up to 245 daysAs given in this study (mouse).

    Source sentences

    Summary
    In none of the 11 mice receiving the GnRH agonist was any tumor found (p < 0.00005), and a significant suppression of the gonadotropins was demonstrated (p < 0.00005).
    2 context sentences
    Summary · context
    All 15 Wx/Wv mice that received sham injections developed bilateral ovarian tubular adenomas from the surface germinal epithelium.
    Summary · context
    We compared tumor development in Wx/Wv mice after either injecting a GnRH agonist (3.6 mg slow-release goserelin depot, Zoladex Depot) or administering a sham injection every 28 days from the age of 7 days up to 245 days.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In Wx/Wv mice, goserelin significantly suppressed gonadotropins (p < 0.00005).

    In plain wordsIn mice, goserelin significantly suppressed gonadotropins.

    Peptide
    Goserelin
    Outcome
    DecreaseGonadotropin suppression
    Study

    mousen = 26

    Wx/Wv mice
    Comparator
    Sham injection
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.6 mg depot every 28 days · injection · from age 7 days up to 245 daysAs given in this study (mouse).

    Source sentences

    Summary
    In none of the 11 mice receiving the GnRH agonist was any tumor found (p < 0.00005), and a significant suppression of the gonadotropins was demonstrated (p < 0.00005).
    1 context sentence
    Summary · context
    We compared tumor development in Wx/Wv mice after either injecting a GnRH agonist (3.6 mg slow-release goserelin depot, Zoladex Depot) or administering a sham injection every 28 days from the age of 7 days up to 245 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.